Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
2016-004129-18Phase 3Terminated
- Sponsor
- Akari Therapeutics
- Start
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of nomacopan in paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), hemolytic uremic syndrome (HUS), sponsored by Akari Therapeutics. Started Dec 2016; status: terminated.
02
Drugs
nomacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)atypical hemolytic uremic syndrome (aHUS)hemolytic uremic syndrome (HUS)
Beyond the preview
Go deeper on 2016-004129-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004129-18.